Conatus Pharmaceuticals (NASDAQ:CNAT) had its target price upped by S&P Equity Research from $5.02 to $5.69 in a research report report published on Wednesday.

Other research analysts have also issued research reports about the company. HC Wainwright reaffirmed a buy rating and set a $17.00 price target (down previously from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Zacks Investment Research lowered Conatus Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, January 16th. Finally, Seaport Global Securities reaffirmed a buy rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Conatus Pharmaceuticals currently has a consensus rating of Buy and an average price target of $12.62.

Shares of Conatus Pharmaceuticals (NASDAQ CNAT) opened at $5.06 on Wednesday. The firm has a market capitalization of $168.63, a P/E ratio of -6.25 and a beta of 1.11. Conatus Pharmaceuticals has a 52 week low of $3.88 and a 52 week high of $9.40. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.08). The business had revenue of $9.57 million for the quarter, compared to analysts’ expectations of $16.06 million. Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. During the same quarter in the previous year, the firm earned ($0.31) EPS. analysts forecast that Conatus Pharmaceuticals will post -0.65 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Conatus Pharmaceuticals by 31.2% during the second quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock worth $5,800,000 after buying an additional 239,373 shares during the period. State Street Corp acquired a new position in Conatus Pharmaceuticals during the second quarter worth approximately $2,092,000. Northern Trust Corp increased its position in Conatus Pharmaceuticals by 640.6% during the second quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock worth $1,712,000 after buying an additional 257,030 shares during the period. Numeric Investors LLC acquired a new position in Conatus Pharmaceuticals during the second quarter worth approximately $1,620,000. Finally, Bank of New York Mellon Corp increased its position in Conatus Pharmaceuticals by 41.2% during the third quarter. Bank of New York Mellon Corp now owns 184,021 shares of the biotechnology company’s stock worth $1,010,000 after buying an additional 53,678 shares during the period. 36.82% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Conatus Pharmaceuticals (CNAT) PT Raised to $5.69 at S&P Equity Research” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://theolympiareport.com/2018/01/25/conatus-pharmaceuticals-cnat-pt-raised-to-5-69-at-sp-equity-research.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.